Candriam SCA’s CONMED CNMD Stock Holding History

Candriam SCA’s Portfolio CNMD Stock Details CNMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-5,048	Closed	-$483K	–	755
2023 Q1	$483K	Buy	+5,048	New	+$488K	﹤0.01%	773

Other funds holding CNMD

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

CIP

Champlain Investment Partners Burlington, Vermont $7.88B AUM 6.82% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Candriam SCA's CNMD Position: Q2 2023 in Review

Candriam SCA sold out of CONMED (CNMD) in Q2 2023, closing a stake of 5,048 shares — an estimated $483K sold.

Candriam SCA first reported a position in CNMD in Q1 2023 and held it in 1 quarter. The position peaked at $483K in Q1 2023. 263 funds tracked by Wall St. Rank hold CNMD as of Q2 2023.

Candriam SCA reported no remaining CONMED position as of Q2 2023 after selling out during the quarter.
Candriam SCA sold 5,048 CONMED shares in Q2 2023, an estimated $483K.
Candriam SCA first reported a position in CONMED in Q1 2023 and held it in 1 quarter.
Candriam SCA's CONMED position peaked at $483K in Q1 2023.
263 funds tracked by Wall St. Rank held CONMED as of Q2 2023.

Based on Candriam SCA's 13F filing for Q2 2023, filed 8 Aug 2023.